Purchase this article with an account.
David Mostafavi, Michael Chang, Vicente Diaz, John Mauro, Sanjay Kedhar, Michael Samson; Duration of Immunomodulator Therapy and Uveitic Relapse. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2516.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the relationship of length of time on immunomodulator therapy (IMT) and relapse of uveitis upon IMT discontinuation.
1100 charts were reviewed at New York Eye and Ear Infirmary from the years 2004-2006. Inclusion criteria included patients who were on Methotrexate or Cellcept for at least 1 year and had a minimum 3 year follow-up period once the medication was discontinued. Three groups were formed: those who were on IMT for 1-2 years, 2-3 years, and greater than 3 years. The first 30 patients who met the inclusion criterion were included in each group. The length of time from IMT discontinuation to relapse was noted.
About half of the patients in the 1-2 year IMT group eventually had a relapse. There was no statistically difference between the 2-3 year and 3 year or greater IMT group.
This pilot study suggests that patients should be treated for a minimum of two years with IMT to minimize the risk of uveitic relapse in the future.
This PDF is available to Subscribers Only